Share Price and Basic Stock Data
Last Updated: January 18, 2026, 6:54 am
| PEG Ratio | 1.10 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Orchid Pharma Ltd operates in the pharmaceuticals sector, with its stock price reported at ₹742 and a market capitalization of ₹3,790 Cr. The company recorded total sales of ₹666 Cr for the fiscal year ending March 2023, reflecting a growth trend from ₹560 Cr in the previous year. For the trailing twelve months (TTM), sales stood at ₹821 Cr, indicating a consistent upward trajectory. Quarterly sales fluctuated, with ₹209.90 Cr in March 2023 peaking at ₹244.41 Cr in June 2024, before slightly declining to ₹222.70 Cr in September 2024. The company’s ability to navigate sales through various quarters demonstrates resilience, although the operating profit margin (OPM) of -0.76% in September 2025 indicates ongoing challenges in maintaining profitability against rising costs. Overall, Orchid Pharma’s revenue trends show a recovery from previous lows, yet the company still faces significant hurdles in achieving sustainable growth.
Profitability and Efficiency Metrics
Orchid Pharma’s profitability metrics reveal a complex picture. The net profit for the fiscal year ending March 2023 was ₹46 Cr, which improved to ₹100 Cr by March 2025. However, the operating profit margin (OPM) has seen volatility, reported at -0.76% in September 2025, signaling inefficiencies in managing operational costs. The interest coverage ratio (ICR) stood at a healthy 9.95x, suggesting that the company can comfortably meet its interest obligations. Furthermore, the return on equity (ROE) reported at 8.21% and return on capital employed (ROCE) at 8.07% indicate moderate efficiency in generating returns for shareholders. The cash conversion cycle (CCC) at 166 days reflects a relatively lengthy process in converting sales into cash, primarily due to inventory management issues. Despite these challenges, the company has shown improvements in its earnings per share (EPS), which rose from ₹11.35 in March 2023 to ₹19.65 in March 2025, highlighting a positive trend in profitability.
Balance Sheet Strength and Financial Ratios
Orchid Pharma’s balance sheet reflects a cautious approach to financing, with total borrowings reported at ₹282 Cr against reserves of ₹1,223 Cr. This indicates a manageable debt level, supported by a total debt-to-equity ratio of 0.13x, well below typical sector benchmarks, suggesting lower financial risk. The company’s current ratio stood at 2.83x, indicating a strong liquidity position, well above the 1.5x threshold that is often considered healthy in the pharmaceuticals sector. However, the price-to-book value (P/BV) ratio of 3.11x suggests that the stock may be overvalued compared to its book value per share of ₹249.86. Additionally, the enterprise value (EV) of ₹3,934.97 Cr and an EV/EBITDA ratio of 27.20 indicate potential overvaluation relative to earnings before interest, taxes, depreciation, and amortization. These metrics show a company that is maintaining a solid financial foundation while navigating the challenges of profitability and valuation.
Shareholding Pattern and Investor Confidence
Orchid Pharma’s shareholding pattern indicates a strong promoter holding of 69.84%, which reflects significant confidence from the company’s founders and management. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), held 1.56% and 19.04% of the shares, respectively, as of the latest reports. The increase in DII holdings from 2.62% in March 2023 to 20.10% in March 2025 demonstrates growing institutional confidence in the company’s recovery and potential. The number of shareholders rose to 38,155, highlighting increasing retail interest despite the company’s mixed financial performance. However, the decline in FII holdings from 8.58% in June 2023 to 1.39% in June 2025 may raise concerns about external investor sentiment. This duality in shareholding patterns underscores a complex view of Orchid Pharma’s market position, balancing strong promoter confidence against fluctuating institutional interest.
Outlook, Risks, and Final Insight
Looking ahead, Orchid Pharma faces both opportunities and risks that could impact its performance. The potential for revenue growth remains strong, driven by improving sales trends and institutional interest. However, the company must address its operational inefficiencies, particularly as reflected in the negative operating profit margin and extended cash conversion cycle. Risks include potential volatility in raw material costs and regulatory pressures that could affect profitability. Additionally, the declining FII interest may pose challenges in attracting foreign investment, which is crucial for long-term growth. To navigate these complexities, a focus on operational efficiency and strategic expansion into profitable segments will be essential. If the company can enhance its profitability metrics while managing costs effectively, it may solidify its position in the competitive pharmaceutical landscape, enabling sustainable growth and improved shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 205/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,884 Cr. | 356 | 479/192 | 80.4 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,986.23 Cr | 1,115.90 | 52.25 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 165.25 | 159.76 | 209.90 | 182.92 | 198.76 | 220.59 | 217.10 | 244.41 | 222.70 | 217.34 | 237.48 | 172.93 | 193.52 |
| Expenses | 147.43 | 146.10 | 170.22 | 160.78 | 175.46 | 185.21 | 188.19 | 211.92 | 192.36 | 190.97 | 209.49 | 158.75 | 194.99 |
| Operating Profit | 17.82 | 13.66 | 39.68 | 22.14 | 23.30 | 35.38 | 28.91 | 32.49 | 30.34 | 26.37 | 27.99 | 14.18 | -1.47 |
| OPM % | 10.78% | 8.55% | 18.90% | 12.10% | 11.72% | 16.04% | 13.32% | 13.29% | 13.62% | 12.13% | 11.79% | 8.20% | -0.76% |
| Other Income | 5.84 | 8.93 | 34.17 | 1.89 | 8.36 | 7.62 | 13.36 | 7.57 | 7.52 | 8.49 | 3.90 | 11.45 | 10.77 |
| Interest | 9.22 | 7.68 | 7.48 | 5.55 | 3.80 | 3.54 | 3.47 | 3.50 | 3.33 | 3.80 | 3.92 | 3.26 | 3.73 |
| Depreciation | 17.76 | 8.18 | 7.21 | 7.71 | 7.84 | 9.27 | 8.42 | 8.44 | 8.63 | 8.61 | 8.87 | 8.65 | 8.90 |
| Profit before tax | -3.32 | 6.73 | 59.16 | 10.77 | 20.02 | 30.19 | 30.38 | 28.12 | 25.90 | 22.45 | 19.10 | 13.72 | -3.33 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -10.27% | -0.53% | 0.00% | 0.00% | -0.21% | 0.00% | 0.00% |
| Net Profit | -5.39 | 7.59 | 59.14 | 9.40 | 19.80 | 29.43 | 32.96 | 29.35 | 27.24 | 20.78 | 22.29 | 14.91 | -5.72 |
| EPS in Rs | -1.32 | 1.86 | 14.49 | 1.85 | 3.90 | 5.80 | 6.50 | 5.79 | 5.37 | 4.10 | 4.39 | 2.94 | -1.13 |
Last Updated: December 29, 2025, 6:04 pm
Below is a detailed analysis of the quarterly data for Orchid Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 193.52 Cr.. The value appears strong and on an upward trend. It has increased from 172.93 Cr. (Jun 2025) to 193.52 Cr., marking an increase of 20.59 Cr..
- For Expenses, as of Sep 2025, the value is 194.99 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 158.75 Cr. (Jun 2025) to 194.99 Cr., marking an increase of 36.24 Cr..
- For Operating Profit, as of Sep 2025, the value is -1.47 Cr.. The value appears to be declining and may need further review. It has decreased from 14.18 Cr. (Jun 2025) to -1.47 Cr., marking a decrease of 15.65 Cr..
- For OPM %, as of Sep 2025, the value is -0.76%. The value appears to be declining and may need further review. It has decreased from 8.20% (Jun 2025) to -0.76%, marking a decrease of 8.96%.
- For Other Income, as of Sep 2025, the value is 10.77 Cr.. The value appears to be declining and may need further review. It has decreased from 11.45 Cr. (Jun 2025) to 10.77 Cr., marking a decrease of 0.68 Cr..
- For Interest, as of Sep 2025, the value is 3.73 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.26 Cr. (Jun 2025) to 3.73 Cr., marking an increase of 0.47 Cr..
- For Depreciation, as of Sep 2025, the value is 8.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.65 Cr. (Jun 2025) to 8.90 Cr., marking an increase of 0.25 Cr..
- For Profit before tax, as of Sep 2025, the value is -3.33 Cr.. The value appears to be declining and may need further review. It has decreased from 13.72 Cr. (Jun 2025) to -3.33 Cr., marking a decrease of 17.05 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -5.72 Cr.. The value appears to be declining and may need further review. It has decreased from 14.91 Cr. (Jun 2025) to -5.72 Cr., marking a decrease of 20.63 Cr..
- For EPS in Rs, as of Sep 2025, the value is -1.13. The value appears to be declining and may need further review. It has decreased from 2.94 (Jun 2025) to -1.13, marking a decrease of 4.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:52 am
| Metric | Sep 2013n n 18m | Mar 2015n n 18m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,948 | 1,747 | 873 | 797 | 683 | 600 | 484 | 450 | 560 | 666 | 819 | 922 | 821 |
| Expenses | 1,837 | 1,429 | 703 | 794 | 659 | 612 | 515 | 421 | 505 | 581 | 708 | 804 | 754 |
| Operating Profit | 110 | 317 | 171 | 3 | 24 | -12 | -31 | 29 | 55 | 84 | 111 | 118 | 67 |
| OPM % | 6% | 18% | 20% | 0% | 4% | -2% | -6% | 7% | 10% | 13% | 14% | 13% | 8% |
| Other Income | 92 | 156 | -28 | -59 | 20 | 218 | 24 | 15 | 67 | 52 | 31 | 27 | 35 |
| Interest | 523 | 537 | 294 | 347 | 310 | 7 | 6 | 52 | 33 | 33 | 17 | 15 | 15 |
| Depreciation | 252 | 325 | 145 | 141 | 133 | 130 | 118 | 109 | 87 | 55 | 33 | 35 | 35 |
| Profit before tax | -573 | -389 | -296 | -544 | -399 | 69 | -131 | -117 | 2 | 48 | 92 | 96 | 52 |
| Tax % | -2% | -49% | -6% | -9% | -12% | 0% | 0% | 0% | 0% | 0% | -3% | -0% | |
| Net Profit | -560 | -197 | -279 | -495 | -353 | 69 | -131 | -117 | -2 | 46 | 92 | 100 | 52 |
| EPS in Rs | -79.21 | -23.06 | -31.37 | -55.69 | -39.65 | 7.80 | -32.11 | -28.55 | -0.48 | 11.35 | 18.17 | 19.65 | 10.30 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -77.42% | 28.69% | 119.55% | -289.86% | 10.69% | 98.29% | 2400.00% | 100.00% | 8.70% |
| Change in YoY Net Profit Growth (%) | 0.00% | 106.11% | 90.86% | -409.40% | 300.54% | 87.60% | 2301.71% | -2300.00% | -91.30% |
Orchid Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | 14% |
| 3 Years: | 18% |
| TTM: | -3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 23% |
| 3 Years: | 249% |
| TTM: | -24% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | % |
| 3 Years: | 33% |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 7% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 11:55 am
Balance Sheet
Last Updated: December 4, 2025, 1:45 am
| Month | Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 70 | 85 | 89 | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 51 | 51 |
| Reserves | 310 | 244 | -40 | -556 | -881 | -793 | 725 | 612 | 607 | 648 | 1,119 | 1,217 | 1,223 |
| Borrowings | 3,204 | 3,211 | 3,215 | 3,106 | 3,202 | 3,230 | 566 | 453 | 268 | 331 | 135 | 175 | 282 |
| Other Liabilities | 1,067 | 521 | 598 | 616 | 715 | 551 | 128 | 132 | 195 | 205 | 249 | 246 | 167 |
| Total Liabilities | 4,651 | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 | 1,722 |
| Fixed Assets | 2,584 | 1,795 | 1,637 | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 633 | 631 |
| CWIP | 360 | 282 | 280 | 288 | 272 | 278 | 26 | 7 | 10 | 46 | 31 | 81 | 120 |
| Investments | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 15 | 45 | 44 | 46 | 50 | 49 |
| Other Assets | 1,706 | 1,984 | 1,944 | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 925 | 922 |
| Total Assets | 4,651 | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 | 1,722 |
Below is a detailed analysis of the balance sheet data for Orchid Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 51.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 51.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,223.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,217.00 Cr. (Mar 2025) to 1,223.00 Cr., marking an increase of 6.00 Cr..
- For Borrowings, as of Sep 2025, the value is 282.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 175.00 Cr. (Mar 2025) to 282.00 Cr., marking an increase of 107.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 167.00 Cr.. The value appears to be improving (decreasing). It has decreased from 246.00 Cr. (Mar 2025) to 167.00 Cr., marking a decrease of 79.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,722.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,688.00 Cr. (Mar 2025) to 1,722.00 Cr., marking an increase of 34.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 631.00 Cr.. The value appears to be declining and may need further review. It has decreased from 633.00 Cr. (Mar 2025) to 631.00 Cr., marking a decrease of 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 81.00 Cr. (Mar 2025) to 120.00 Cr., marking an increase of 39.00 Cr..
- For Investments, as of Sep 2025, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 922.00 Cr.. The value appears to be declining and may need further review. It has decreased from 925.00 Cr. (Mar 2025) to 922.00 Cr., marking a decrease of 3.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,722.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,688.00 Cr. (Mar 2025) to 1,722.00 Cr., marking an increase of 34.00 Cr..
Notably, the Reserves (1,223.00 Cr.) exceed the Borrowings (282.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2015n n 18m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2013n n 18m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 317.00 | 168.00 | 0.00 | 21.00 | -15.00 | -597.00 | -424.00 | -213.00 | -247.00 | -24.00 | -57.00 | 110.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 34 | 54 | 130 | 75 | 64 | 73 | 51 | 110 | 111 | 118 | 87 | 96 |
| Inventory Days | 187 | 118 | 220 | 196 | 202 | 214 | 254 | 244 | 201 | 217 | 199 | 219 |
| Days Payable | 220 | 146 | 341 | 402 | 374 | 381 | 182 | 176 | 195 | 165 | 173 | 149 |
| Cash Conversion Cycle | -0 | 26 | 9 | -130 | -108 | -94 | 123 | 179 | 117 | 170 | 113 | 166 |
| Working Capital Days | -399 | -49 | -168 | -500 | -876 | -1,158 | 166 | 302 | 97 | 54 | 118 | 135 |
| ROCE % | -3% | 1% | 1% | -4% | -4% | -5% | -6% | -5% | -2% | 5% | 9% | 8% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 3,465,947 | 0.96 | 288.78 | 1,534,919 | 2025-12-07 17:25:17 | 125.81% |
| Invesco India Contra Fund | 990,763 | 0.4 | 82.55 | N/A | N/A | N/A |
| UTI Value Fund | 745,230 | 0.61 | 62.09 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 457,561 | 0.45 | 38.12 | 492,727 | 2025-12-14 10:47:08 | -7.14% |
| Invesco India Smallcap Fund | 455,183 | 0.42 | 37.93 | N/A | N/A | N/A |
| Bandhan Small Cap Fund | 294,201 | 0.13 | 24.51 | N/A | N/A | N/A |
| UTI Small Cap Fund | 283,362 | 0.49 | 23.61 | 445,000 | 2025-12-08 01:35:25 | -36.32% |
| Invesco India ELSS Tax Saver Fund | 131,909 | 0.39 | 10.99 | 153,202 | 2025-12-15 04:04:57 | -13.9% |
| Kotak Multicap Fund | 114,308 | 0.04 | 9.52 | N/A | N/A | N/A |
| UTI Healthcare Fund | 100,000 | 0.74 | 8.33 | 100,000 | 2025-04-22 17:25:24 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 19.65 | 19.06 | 11.35 | -0.48 | -28.55 |
| Diluted EPS (Rs.) | 19.65 | 19.06 | 11.35 | -0.48 | -28.55 |
| Cash EPS (Rs.) | 25.69 | 25.30 | 25.30 | 21.71 | -1.87 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 249.86 | 230.58 | 168.72 | 158.61 | 159.96 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 249.86 | 230.58 | 168.72 | 158.61 | 159.96 |
| Revenue From Operations / Share (Rs.) | 181.77 | 161.55 | 163.14 | 137.09 | 110.26 |
| PBDIT / Share (Rs.) | 28.52 | 27.91 | 25.25 | 15.22 | 15.93 |
| PBIT / Share (Rs.) | 21.71 | 21.35 | 11.82 | -6.10 | -10.76 |
| PBT / Share (Rs.) | 18.84 | 18.13 | 13.54 | -13.94 | -23.34 |
| Net Profit / Share (Rs.) | 18.88 | 18.74 | 11.88 | 0.38 | -28.55 |
| NP After MI And SOA / Share (Rs.) | 19.65 | 18.17 | 11.35 | -0.47 | -28.55 |
| PBDIT Margin (%) | 15.69 | 17.27 | 15.47 | 11.10 | 14.44 |
| PBIT Margin (%) | 11.94 | 13.21 | 7.24 | -4.44 | -9.75 |
| PBT Margin (%) | 10.36 | 11.22 | 8.29 | -10.16 | -21.16 |
| Net Profit Margin (%) | 10.38 | 11.60 | 7.27 | 0.28 | -25.89 |
| NP After MI And SOA Margin (%) | 10.80 | 11.24 | 6.95 | -0.34 | -25.89 |
| Return on Networth / Equity (%) | 7.86 | 7.88 | 6.72 | -0.30 | -17.84 |
| Return on Capital Employeed (%) | 7.85 | 8.37 | 5.65 | -2.86 | -4.00 |
| Return On Assets (%) | 5.90 | 5.93 | 3.78 | -0.17 | -9.41 |
| Long Term Debt / Equity (X) | 0.10 | 0.10 | 0.21 | 0.32 | 0.65 |
| Total Debt / Equity (X) | 0.13 | 0.11 | 0.48 | 0.41 | 0.65 |
| Asset Turnover Ratio (%) | 0.56 | 0.58 | 0.57 | 0.47 | 0.30 |
| Current Ratio (X) | 2.83 | 3.04 | 1.35 | 1.87 | 3.87 |
| Quick Ratio (X) | 1.68 | 2.03 | 0.73 | 1.15 | 2.79 |
| Inventory Turnover Ratio (X) | 3.12 | 2.14 | 2.02 | 2.09 | 1.60 |
| Interest Coverage Ratio (X) | 9.95 | 8.65 | 3.20 | 1.94 | 1.27 |
| Interest Coverage Ratio (Post Tax) (X) | 7.59 | 6.81 | 1.50 | -0.77 | -0.85 |
| Enterprise Value (Cr.) | 3934.97 | 5169.07 | 1869.70 | 1420.30 | 10472.28 |
| EV / Net Operating Revenue (X) | 4.27 | 6.31 | 2.81 | 2.54 | 23.27 |
| EV / EBITDA (X) | 27.20 | 36.52 | 18.14 | 22.86 | 161.10 |
| MarketCap / Net Operating Revenue (X) | 4.27 | 6.47 | 2.36 | 2.07 | 22.36 |
| Price / BV (X) | 3.11 | 4.53 | 2.28 | 1.79 | 15.41 |
| Price / Net Operating Revenue (X) | 4.27 | 6.47 | 2.36 | 2.07 | 22.36 |
| EarningsYield | 0.02 | 0.01 | 0.02 | 0.00 | -0.01 |
After reviewing the key financial ratios for Orchid Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 19.65. This value is within the healthy range. It has increased from 19.06 (Mar 24) to 19.65, marking an increase of 0.59.
- For Diluted EPS (Rs.), as of Mar 25, the value is 19.65. This value is within the healthy range. It has increased from 19.06 (Mar 24) to 19.65, marking an increase of 0.59.
- For Cash EPS (Rs.), as of Mar 25, the value is 25.69. This value is within the healthy range. It has increased from 25.30 (Mar 24) to 25.69, marking an increase of 0.39.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 249.86. It has increased from 230.58 (Mar 24) to 249.86, marking an increase of 19.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 249.86. It has increased from 230.58 (Mar 24) to 249.86, marking an increase of 19.28.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 181.77. It has increased from 161.55 (Mar 24) to 181.77, marking an increase of 20.22.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.52. This value is within the healthy range. It has increased from 27.91 (Mar 24) to 28.52, marking an increase of 0.61.
- For PBIT / Share (Rs.), as of Mar 25, the value is 21.71. This value is within the healthy range. It has increased from 21.35 (Mar 24) to 21.71, marking an increase of 0.36.
- For PBT / Share (Rs.), as of Mar 25, the value is 18.84. This value is within the healthy range. It has increased from 18.13 (Mar 24) to 18.84, marking an increase of 0.71.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 18.88. This value is within the healthy range. It has increased from 18.74 (Mar 24) to 18.88, marking an increase of 0.14.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 19.65. This value is within the healthy range. It has increased from 18.17 (Mar 24) to 19.65, marking an increase of 1.48.
- For PBDIT Margin (%), as of Mar 25, the value is 15.69. This value is within the healthy range. It has decreased from 17.27 (Mar 24) to 15.69, marking a decrease of 1.58.
- For PBIT Margin (%), as of Mar 25, the value is 11.94. This value is within the healthy range. It has decreased from 13.21 (Mar 24) to 11.94, marking a decrease of 1.27.
- For PBT Margin (%), as of Mar 25, the value is 10.36. This value is within the healthy range. It has decreased from 11.22 (Mar 24) to 10.36, marking a decrease of 0.86.
- For Net Profit Margin (%), as of Mar 25, the value is 10.38. This value exceeds the healthy maximum of 10. It has decreased from 11.60 (Mar 24) to 10.38, marking a decrease of 1.22.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.80. This value is within the healthy range. It has decreased from 11.24 (Mar 24) to 10.80, marking a decrease of 0.44.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.86. This value is below the healthy minimum of 15. It has decreased from 7.88 (Mar 24) to 7.86, marking a decrease of 0.02.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.85. This value is below the healthy minimum of 10. It has decreased from 8.37 (Mar 24) to 7.85, marking a decrease of 0.52.
- For Return On Assets (%), as of Mar 25, the value is 5.90. This value is within the healthy range. It has decreased from 5.93 (Mar 24) to 5.90, marking a decrease of 0.03.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.13. This value is within the healthy range. It has increased from 0.11 (Mar 24) to 0.13, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has decreased from 0.58 (Mar 24) to 0.56, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 2.83. This value is within the healthy range. It has decreased from 3.04 (Mar 24) to 2.83, marking a decrease of 0.21.
- For Quick Ratio (X), as of Mar 25, the value is 1.68. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.68, marking a decrease of 0.35.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.12. This value is below the healthy minimum of 4. It has increased from 2.14 (Mar 24) to 3.12, marking an increase of 0.98.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 9.95. This value is within the healthy range. It has increased from 8.65 (Mar 24) to 9.95, marking an increase of 1.30.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.59. This value is within the healthy range. It has increased from 6.81 (Mar 24) to 7.59, marking an increase of 0.78.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,934.97. It has decreased from 5,169.07 (Mar 24) to 3,934.97, marking a decrease of 1,234.10.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.27. This value exceeds the healthy maximum of 3. It has decreased from 6.31 (Mar 24) to 4.27, marking a decrease of 2.04.
- For EV / EBITDA (X), as of Mar 25, the value is 27.20. This value exceeds the healthy maximum of 15. It has decreased from 36.52 (Mar 24) to 27.20, marking a decrease of 9.32.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.27. This value exceeds the healthy maximum of 3. It has decreased from 6.47 (Mar 24) to 4.27, marking a decrease of 2.20.
- For Price / BV (X), as of Mar 25, the value is 3.11. This value exceeds the healthy maximum of 3. It has decreased from 4.53 (Mar 24) to 3.11, marking a decrease of 1.42.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.27. This value exceeds the healthy maximum of 3. It has decreased from 6.47 (Mar 24) to 4.27, marking a decrease of 2.20.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Orchid Pharma Ltd:
- Net Profit Margin: 10.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.85% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.86% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.59
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.68
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 70.3 (Industry average Stock P/E: 52.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.13
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Alathur, Chengalpattu Tamil Nadu 600110 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ram Gopal Agarwal | Chairman & Non-Exe.Director |
| Mr. Manish Dhanuka | Managing Director |
| Mr. Mridul Dhanuka | Whole Time Director |
| Mr. Arjun Dhanuka | Non Executive Director |
| Mrs. Tanu Singla | Independent Woman Director |
| Dr. Dharam Vir | Independent Director |
| Dr. Manoj Kumar Goyal | Independent Director |
| Ms. Shubha Singh | Independent Woman Director |
FAQ
What is the intrinsic value of Orchid Pharma Ltd?
Orchid Pharma Ltd's intrinsic value (as of 18 January 2026) is ₹1935.93 which is 167.39% higher the current market price of ₹724.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,674 Cr. market cap, FY2025-2026 high/low of ₹1,670/604, reserves of ₹1,223 Cr, and liabilities of ₹1,722 Cr.
What is the Market Cap of Orchid Pharma Ltd?
The Market Cap of Orchid Pharma Ltd is 3,674 Cr..
What is the current Stock Price of Orchid Pharma Ltd as on 18 January 2026?
The current stock price of Orchid Pharma Ltd as on 18 January 2026 is ₹724.
What is the High / Low of Orchid Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Orchid Pharma Ltd stocks is ₹1,670/604.
What is the Stock P/E of Orchid Pharma Ltd?
The Stock P/E of Orchid Pharma Ltd is 70.3.
What is the Book Value of Orchid Pharma Ltd?
The Book Value of Orchid Pharma Ltd is 251.
What is the Dividend Yield of Orchid Pharma Ltd?
The Dividend Yield of Orchid Pharma Ltd is 0.00 %.
What is the ROCE of Orchid Pharma Ltd?
The ROCE of Orchid Pharma Ltd is 8.07 %.
What is the ROE of Orchid Pharma Ltd?
The ROE of Orchid Pharma Ltd is 8.21 %.
What is the Face Value of Orchid Pharma Ltd?
The Face Value of Orchid Pharma Ltd is 10.0.